clevudine
Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir. — Wikipedia
Clinical trial activity
30 trials · 18 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2002 (NCT00305019)
Timeline
Indications
Approved for
Mechanism of action
- Protein PINHIBITOR
P inhibitor
Clevudine is phosphorylated inside the cell to its active form, clevudine triphosphate (clevudine-TP). Clevudine-TP binds to the viral polymerase active site (or a site very close to it) inhibiting the protein priming and viral DNA synthesis. It is suggested that its binding to the viral polymerase active site alters its structure such that the viral polymerase is unable to bind or incorporate any of the natural dNMP substrates.
Chemistry & pharmacology
SMILES
Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O- Mol. weight
- 260.22 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaClevudine ↗
- ChEMBLCHEMBL458875 ↗
Also known as
- 1-(2-fluoro-2-deoxy-beta-arabinofuranosyl)thymine
- 1-(2-fluoro-2-deoxy-beta-d-arabinofuranosyl)thymine
- 1-(2-fluoro-5-methyl-beta,l-arabinofuranosyl)uracil
- 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-methyl-
- 2'-deoxy-2'-fluoroarabinofuranosylthymine
- 2'-fluoro-1-beta-arabinofuranosyl-5-methyluracil
- 2'-fluoro-5-methyl-1-beta-arabinosyluracil
- 2'-fluoro-5-methyl-1-beta-d-arabinofuranosyluracil
- 2'-fluoro-5-methylarabinosyluracil
- 2'-fluoro-5-methylarabinosyluracil, 2-(14)c-labeled
- 5-methyl-2'-fluoroarauracil
- clevudine
- clevudine
- clevudine
- clevudine
- clevudine
- clevudine
- clevudine
- d-fmau
- d-fmau
- d-fmau
- fmau
- levovir
- levovir
- levovir
- l-fmau
- l-fmau
- l-fmau
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04891302 | Phase 2 | Mar 19, 2021 | Bukwang Pharmaceutical |
| NCT04347915 | Phase 2 | Apr 24, 2020 | Bukwang Pharmaceutical, Korea University |
| NCT02809690 | N/A | Sep 1, 2016 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Southern California |
| NCT02079181 | N/A | Jan 31, 2014 | National Cancer Institute (NCI), University of Southern California |
| NCT01812668 | N/A | Mar 1, 2013 | Wayne State University |
| NCT01581242 | Phase 1 | Apr 1, 2012 | Bukwang Pharmaceutical |
| NCT01263002 | Phase 4 | Jun 1, 2010 | Bukwang Pharmaceutical |
| NCT01264354 | Phase 4 | Mar 1, 2010 | Bukwang Pharmaceutical |
| NCT01192854 | Phase 3 | Feb 1, 2010 | Central South University, Eisai |
| NCT01264094 | Phase 4 | Nov 1, 2009 | Bukwang Pharmaceutical |
| NCT01264133 | Phase 4 | Sep 1, 2009 | Bukwang Pharmaceutical |
| NCT01266005 | Phase 4 | Aug 1, 2009 | Bukwang Pharmaceutical |
| NCT00798460 | Phase 4 | Dec 1, 2008 | Bukwang Pharmaceutical, Inje University |
| NCT00823342 | Phase 3 | Dec 1, 2008 | French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Pharmasset |
| NCT01264367 | Phase 4 | Dec 1, 2008 | Bukwang Pharmaceutical, Catholic University of Korea |
| NCT00641082 | Phase 4 | Feb 1, 2008 | Bukwang Pharmaceutical |
| NCT00672867 | Phase 3 | Dec 1, 2007 | Bukwang Pharmaceutical |
| NCT00558493 | Phase 4 | Nov 1, 2007 | Bukwang Pharmaceutical |
| NCT00496002 | Phase 3 | Aug 1, 2007 | Pharmasset |
| NCT00496158 | Phase 3 | Aug 1, 2007 | Pharmasset |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bukwang Pharmaceutical | For profit | 22 | 21 | 4 | 2002 |
| Seoul National University | Academic/Hospital | 6 | 0 | 2 | 2002 |
| Pharmasset | For profit | 3 | 2 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2014 |
| University of Southern California | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Chungnam National University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Eisai | For profit | 1 | 1 | 1 | 2010 |
| Eulji University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| French National Agency for Research on AIDS and Viral Hepatitis | Government | 1 | 1 | 1 | 2008 |
| Gilead Sciences | For profit | 1 | 0 | 1 | 2008 |
| Inje University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2016 |
| The University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Triangle Pharmaceuticals | For profit | 1 | 1 | 1 | 2002 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 2013 |